NCT05785468 (ROSCAPLI) is a clinical trial of Caplacizumab in Thrombotic Thrombocytopenic Purpura, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT05785468?

NCT05785468 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT05785468?

Interventions in NCT05785468: Caplacizumab.

What condition does NCT05785468 study?

NCT05785468 studies Thrombotic Thrombocytopenic Purpura.

Is NCT05785468 still recruiting?

NCT05785468 is currently status unknown. Last updated 27 March 2023.

Last reviewed 2023-03-27 · How we verify

NCT05785468: ROSCAPLI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)

Status unknown Last updated 27 March 2023

What this trial tests

trial testing Caplacizumab in Thrombotic Thrombocytopenic Purpura in 1 participant. Status unknown.

Timeline

21 October 2021

Primary endpoint
30 March 2023

30 March 2023

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1
Start date	21 October 2021
Primary completion	30 March 2023
Estimated completion	30 March 2023
Sites	1 location across Italy

Drugs / interventions tested

Caplacizumab (CAPLACIZUMAB) — full drug profile →

Conditions studied

Thrombotic Thrombocytopenic Purpura — all drugs for Thrombotic Thrombocytopenic Purpura →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

Eligibility, any sex, with Thrombotic Thrombocytopenic Purpura. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated \[1\]. TTP is a prototype of the thrombotic microangiopathies (TMAs), and it is characterized by disseminated formation of platelet-rich thrombi in arterioles and capillaries resulting in microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and potential end-organ injury mainly involving the brain, heart, and kidneys leading to significant morbidity/mortality

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.
Fan Y, Feng R, Zhang X, Wang ZL, et al · · 2024 · cited 22× · PMID 39220863 · DOI 10.1016/j.apsb.2024.04.006

Verify or expand the search:

Other trials of Caplacizumab

Trials testing the same drug.

NCT05468320 — Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated · Phase 3 · completed
NCT05263193 — Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP) · completed
NCT04720261 — Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP · Phase 2 · terminated
NCT02878603 — Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) · Phase 3 · completed

Other recruiting trials for Thrombotic Thrombocytopenic Purpura

Currently open trials in the same condition.

NCT06727669 — Longitudinal Cohort of Thrombosis and Hemostasis Diseases · recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05785468 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 27 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05785468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing